Hims & Hers Health, Inc. (NYSE:HIMS) Stock Has Consensus Target Price of $32.43

Key Points

• Analyst consensus is “Hold”: Of 15 analysts covering Hims & Hers Health, 11 rate it a hold, three recommend buying and one recommends selling. The average 12-month price target is $32.43.
• Institutional ownership remains substantial: Institutional investors and hedge funds own 63.52% of the stock, with Bank of America and other major investors recently increasing their positions. Insiders, however, sold 130,443 shares worth about $3.7 million over the past 90 days.
• Growth is mixed with notable risks: Quarterly revenue rose 38.2% year over year to $753.2 million, but the company missed EPS estimates and remained unprofitable. New product and international expansions support growth, while regulatory and legal allegations add uncertainty.

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) have been given a consensus recommendation of "Hold" by the fifteen ratings firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $32.43.

A number of research analysts have recently commented on the stock. Citigroup decreased their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set a "neutral" rating for the company in a research report on Tuesday, August 11th. Zacks Research raised shares of Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research report on Monday, July 13th. Canaccord Genuity Group raised their target price on shares of Hims & Hers Health from $32.00 to $40.00 and gave the stock a "buy" rating in a research note on Wednesday, July 1st. Truist Financial raised their target price on shares of Hims & Hers Health from $27.00 to $32.00 and gave the stock a "hold" rating in a research note on Monday, August 24th. Finally, TD Cowen lifted their target price on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a "hold" rating in a report on Tuesday, August 11th.

Insider Buying and Selling

In other news, insider Deborah M. Autor sold 16,773 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $27.85, for a total value of $467,128.05. Following the sale, the insider directly owned 48,961 shares in the company, valued at approximately $1,363,563.85. This trade represents a 25.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 25,111 shares of the firm's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $27.55, for a total value of $691,808.05. Following the sale, the insider directly owned 313,964 shares in the company, valued at approximately $8,649,708.20. This trade represents a 7.41% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 130,443 shares of company stock valued at $3,731,426 over the last 90 days. 11.76% of the stock is currently owned by insiders.

Institutional Trading of Hims & Hers Health

Large investors have recently bought and sold shares of the business. Bank of America Corp DE raised its holdings in Hims & Hers Health by 194.4% during the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company's stock worth $90,465,000 after buying an additional 2,877,550 shares during the last quarter. State of Michigan Retirement System raised its stake in shares of Hims & Hers Health by 13.7% in the first quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company's stock worth $48,549,000 after purchasing an additional 280,900 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Hims & Hers Health in the second quarter valued at approximately $46,220,000. Principal Financial Group Inc. lifted its stake in Hims & Hers Health by 97.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,282,266 shares of the company's stock valued at $26,620,000 after acquiring an additional 632,282 shares in the last quarter. Finally, Bienville Capital Management LLC purchased a new position in Hims & Hers Health during the 2nd quarter worth $27,242,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Expanded men’s health portfolio: Hims & Hers launched injectable and oral testosterone replacement therapies for eligible men, its largest men’s health expansion since entering the category. The broader product range could increase customer acquisition, engagement and revenue in a sizable market. Hims Expands Testosterone Care with Injectable and Oral TRT
• Positive Sentiment: European growth: The company launched an online weight-management service for men in Germany, allowing eligible users to receive prescriptions from European Union-licensed clinicians and ongoing support. The move expands Hims & Hers’ addressable market and helped drive a recent increase in the stock. Hims & Hers launches men’s weight care in Germany
• Neutral Sentiment: Membership momentum: A report said Hims & Hers is approaching three million members, suggesting continued platform adoption and potential operating leverage, although the milestone does not provide new formal financial guidance. Hims Is Reaching the Three Million Member Milestone
• Negative Sentiment: Regulatory and legal overhang: Multiple law firms publicized a securities class action against Hims & Hers following allegations in an FTC complaint concerning business practices, including privacy and billing issues. The lawsuit covers investors who purchased shares from August 4, 2025, through July 29, 2026, with a lead-plaintiff deadline of November 2, 2026. The allegations could increase legal costs, reputational risk and uncertainty around future operations; they have not been proven in court. Hims & Hers faces securities class action after FTC complaint

Hims & Hers Health Price Performance

HIMS opened at $29.19 on Thursday. The company's 50 day simple moving average is $29.13 and its 200-day simple moving average is $28.99. The stock has a market capitalization of $6.81 billion, a P/E ratio of -46.33 and a beta of 2.44. Hims & Hers Health has a one year low of $13.74 and a one year high of $50.99. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The business had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business's revenue was up 38.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.17 EPS. Sell-side analysts anticipate that Hims & Hers Health will post -0.16 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides telehealth services through the Hims and Hers platforms. The company connects consumers with licensed healthcare providers through online consultations and offers access to prescription and over-the-counter products, as well as educational and wellness resources.

Its services address areas including sexual health, hair loss, skincare, mental health, weight management and primary care. Depending on the condition and eligibility requirements, customers may receive personalized treatment plans and have prescribed medications delivered directly to them.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.